BALCAO · SERVICES-MEDICAL LABORATORIES
Renalytix PLC RNLXY
6 fiscal years on record · USD · FY2023 reported
SEC FILINGS ONLY
Revenue · FY2023
$2.3M
▼ 32.7% vs FY2022
EPS · FY23
$-0.31
Dividend / sh · FY23
—
Payout · FY23
—
ROE · FY23
—
Net margin · FY23
-1461.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.3M
Revenue, FY2023 · full 6-year series below
Revenue
Net income
The company lost 1462 cents on every revenue dollar this year.
Per share
USD -0.31
Diluted EPS, FY2023
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2023
ROE
Operating margin-1293.5%
Net margin-1461.6%
Return on assets-173.3%
Returned to shareholders
—
returned in FY2023 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+15.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.15B
Shares outstanding, FY2023
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.0M
total assets, end of FY2023
Total assetsUSD 8.0M
EquityUSD -7.9M
CashUSD 4.7M
Current ratio0.53×
Equity funds -99% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.31
−0.55
−0.67
−0.49
−0.17
−0.99
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
·
−242.8
−88.7
−80.9
−80.5
−494.7
Shares out B
0.15
0.09
0.07
0.07
0.06
0.05
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
23 of 23
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed